ArticleVeterinary world2026
Camel plasma as an innovative non-antibiotic therapy for
Article in Veterinary world, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Neonatal colibacillosis caused by Materials and Methods: Rectal swab samples from 10 naturally diarrheic lambs were initially collected and subjected to bacteriological culture on MacConkey and Eosin methylene blue agars, followed by polymerase chain reaction (PCR) targeting the Results: All isolates were confirmed as Conclusion: Camel plasma demonstrated superior therapeutic efficacy compared with antibiotics, camel milk, and probiotics in improving clinical signs, modulating inflammatory responses, and supporting passive immunity in neonatal lambs with colibacillosis. As a promising non-antibiotic intervention, camel plasma has the potential to reduce antimicrobial use, limit the spread of AMR, enhance farm biosecurity, and decrease the risk of zoonotic transmission in resource-limited settings. These findings strongly support further large-scale, long-term studies to validate safety, optimize dosing, and explore broader applications within a One Health framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.